Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HOLX

Is Hologic Stock Outperforming the Nasdaq?

While Hologic has underperformed the Nasdaq over the past year, it has notably outperformed in recent months, but analysts still remain cautious about the stock’s prospects.

Barchart

Hologic Agrees To $18.3 Billion Buyout By Blackstone And TPG

Hologic, Inc. (NASDAQ:HOLX) shares are trading higher after the company agreed to be acquired by funds managed by Blackstone Inc. (NYSE:BX) and TPG Inc. (NASDAQ:TPG) for an enterprise value of about $18.3 billion.

Benzinga

What to Expect From Hologic’s Next Quarterly Earnings Report

Hologic is set to release its fourth-quarter earnings next month, and analysts are forecasting a solid high-single-digit increase in profits.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What Are Wall Street Analysts' Target Price for Hologic Stock?

Although Hologic has underperformed the broader market over the past year, it has observed significant gains in recent months, and analysts are turning more optimistic on the stock’s prospects.

Barchart

What to Expect From Hologic's Q3 2025 Earnings Report

Hologic is scheduled to report its third-quarter results later this month, and analysts are projecting a marginal decline in profits.

Barchart

How Is Hologic’s Stock Performance Compared to Other Health Care Equipment Stocks?

Hologic has outpaced its healthcare equipment peers over the past year, with analysts maintaining a moderately bullish outlook on the stock’s future performance.

Barchart

Here's What to Expect From Hologic’s Next Earnings Report

Hologic is scheduled to release its first-quarter results next month, and analysts are projecting single-digit dip in its bottom-line figure.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Hologic Stock: Is HOLX Underperforming the Healthcare Sector?

Hologic has notably underperformed the healthcare sector over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Hologic Stock: Analyst Estimates & Ratings

Hologic has observed a significant drop in stock prices recently and analysts are taking a more cautious stance on the company’s prospects.

Barchart

Earnings Preview: What To Expect From Hologic's Report

Hologic is scheduled to release its first-quarter results next month, with analysts projecting single-digit growth in its bottom line figure.

Barchart

Is Hologic Stock Underperforming the Dow?

Hologic has lagged behind the Dow index over the past three months, yet analysts remain cautiously optimistic about the stock's growth potential.

Barchart

Do Wall Street Analysts Like Hologic Stock?

Hologic has underperformed the broader market over the past year, but Wall Street analysts are moderately optimistic about the stock’s future.

Barchart

Hologic's Quarterly Earnings Preview: What You Need to Know

Hologic is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

Barchart

3 Medical Device Stocks With Strong Growth Prospects

The medical industry is on the fence of explosive growth, fueled by technological advancements. In this evolving landscape, investors could consider investing in promising medical device stocks like Hologic, Inc. (HOLX), Avanos Medical (AVNS), and Embecta Corp. (EMBC) with solid growth prospects. Learn more….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Hologic Stock Outperforming the Nasdaq?

Hologic has recently outperformed in the Nasdaq, and Wall Street analysts are moderately bullish about the stock’s prospects.

StockNews.com

3 MedTech Stocks Revolutionizing Healthcare

MedTech stocks are at the forefront of revolutionizing healthcare with the dynamic growth potential of technology. Amid this backdrop, it could be wise to consider investing in companies like Medtronic (MDT), STERIS (STE), and Hologic (HOLX), which are transforming the way healthcare is delivered and tailoring it to individual patient…

Barchart

Hologic Stock Outlook: Is Wall Street Bullish or Bearish?

Hologic has lagged the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Hologic's Q3 2024 Earnings: What to Expect

Hologic is expected to report its third-quarter earnings results this month, and Wall Street analysts expect a single-digit profit growth.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Hologic's Return On Capital Employed Overview

Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters.

Benzinga

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Hologic Inc (NASDAQ:HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales. Hologic's global diagnostics business posted revenues of $987.1 million, down 7%. Diagnostics revenues excluding COVID-19 revenues…

Benzinga

Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours, at $69.37 per share. A move to $83.00 would account for a 19.65% increase from the current…

Benzinga

Expert Ratings for Hologic

Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter:

Benzinga

Death Cross Looms Over Hologic Investors

If history is any guide, there may be trouble ahead for shares of Hologic (NASDAQ:HOLX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Analyst Ratings For Hologic

Over the past 3 months, 5 analysts have published their opinion on Hologic (NASDAQ:HOLX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Looking Into Hologic's Return On Capital Employed

According to Benzinga Pro, during Q1, Hologic (NASDAQ:HOLX) earned $499.20 million, a 51.82% increase from the preceding quarter. Hologic also posted a total of $1.47 billion in sales, a 11.69% increase since Q4.

1 2

Organisations

Medical Devices Equipment

13 stories

EMBC

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

325,844 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.